Status:
UNKNOWN
Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects
Lead Sponsor:
Keymed Biosciences Co.Ltd
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.
Detailed Description
This study includes screening and treatment and follow-up periods.
Eligibility Criteria
Inclusion
- 20 years ≤ age ≤ 45 years.
- Voluntarily participate in the study and sign the ICF.
- Have the ability to understand the study.
Exclusion
- With history of chronic or serious illness.
- With any medication within 28 days prior to administration;
- Plan to undergo surgery during the research period;
- With any situations unsuitable to participate in this study.
Key Trial Info
Start Date :
April 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2025
Estimated Enrollment :
236 Patients enrolled
Trial Details
Trial ID
NCT06171048
Start Date
April 30 2024
End Date
April 30 2025
Last Update
December 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Hospital of Anhui Medical University
Hefei, Anhui, China